Search

Displaying results 6961 - 6970 of 8170 in total
  1. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.

  2. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    IMC-1C11 is an anti-angiogenesis agent.

  3. Drug

    Ertiprotafib

    go.drugbank.com/drugs/DB06521
    Experimental

    In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test.

  4. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.

  5. Drug

    Inhibitor of P38 Kinase

    go.drugbank.com/drugs/DB01953
    Experimental

    These are compounds containing an indole moiety, which consists of a pyrrole ring fused to benzene to form 2,3-benzopyrrole. This drug is known to target mitogen-activated protein kinase 14.

  6. Drug

    AMG-222

    go.drugbank.com/drugs/DB06011
    Experimental

  7. Drug

    Felezonexor

    go.drugbank.com/drugs/DB21067
    Investigational

    Felezonexor has a monoisotopic molecular weight of 419.12 Da.

  8. Drug

    Edaxeterkib

    go.drugbank.com/drugs/DB21490
    Investigational

    Edaxeterkib has a monoisotopic molecular weight of 469.22 Da.

  9. Drug

    Telenzepine

    go.drugbank.com/drugs/DB19508
    Investigational

    Telenzepine has a monoisotopic molecular weight of 370.15 Da.

  10. Drug

    Setileuton

    go.drugbank.com/drugs/DB19550
    Investigational

    Setileuton has a monoisotopic molecular weight of 463.12 Da.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates